Merck & Company, Inc.
MRK · NYSE
MRK · NYSE
Merck sells prescription medicines, vaccines, and animal-health products. Human health is the core business, led by oncology and particularly Keytruda, while vaccines and other pharmaceutical products provide additional revenue; Merck also serves the animal-health market. Customers include patients through physicians, hospitals, pharmacies, distributors, governments, and veterinary providers. The company operates at large global scale, reporting $65.0 billion of fiscal 2025 revenue and $18.3 billion of net income, compared with $64.2 billion and $17.1 billion, respectively, in fiscal 2024. The supplied evidence also describes a potential $70 billion pipeline and expanded Keytruda trial reach.
Merck fell $5.48, or 3.65%, from $150.33 to $144.85 over the week. The supplied evidence does not identify a company-specific announcement, analyst action, earnings release, or guidance change that explains the decline. Trading had already weakened from $150.33 on September 4 to $143.93 on September 11, including a $2.82 drop on September 10, before the stock recovered modestly on September 14. The move therefore appears to have reflected continued selling pressure rather than a clearly documented new catalyst. Available articles frame the central issues as valuation, dividend sustainability, Keytruda’s growth and trial expansion, and whether Merck’s pipeline can offset future pressure, but none is tied to a dated event during this week. Broader market context is not supplied.
Merck shares gained 0.47%, rising from $147.76 to $148.46, despite a sharp late-week reversal. The stock had climbed from $149.86 on September 1 to $152.34 on September 3, but gave back most of that advance with a 1.32% drop on September 4 and another 1.24% decline on September 8. The supplied evidence does not identify a company-specific announcement driving the move. Instead, coverage portrayed Merck as relatively flat while Moderna rallied, suggesting muted sector-relative performance. Investor attention remained centered on Keytruda’s eventual loss of exclusivity, pipeline progress, and whether newer cancer drugs can offset that exposure, while analyst target increases provided some support.
Merck rose 1.87%, from $149.54 to $152.34 over the week. The stock first fell to $147.76 on Monday, extending the prior Friday’s decline, then reversed higher for three consecutive sessions, gaining $4.58 from Monday’s close through Thursday. The strongest apparent company-specific support was Wells Fargo maintaining its Merck view while raising its price target to $170, although the supplied evidence does not establish that the action directly drove any particular session. Investors also weighed longer-term product risks, including another Alzheimer’s trial cancellation under the Neuphoria partnership and debate over Keytruda’s durability. The record provides no clear market-wide catalyst or evidence linking those reports to the daily moves, so the week was primarily a recovery after Monday’s dip.
Merck finished the comparison period up $0.55, or 0.37%, at $149.54 from $148.99. The week was materially more volatile than the net change suggests: shares fell 1.24% on Monday from Friday’s $152.55 close, jumped 3.84% on Tuesday to $156.45, then gave back the entire advance over the next two sessions, falling 4.41% to Thursday’s close. Coverage cited positive melanoma data, pipeline progress, new launches and M&A as support for the rally, while Argus raised its target to $170. A court rejection of Merck’s challenge to Medicare drug-price negotiation was a counterweight. No single dated company announcement explains the full reversal, and volume fell sharply late in the period.
Merck gained $13.44, or 9.92%, over the measured week, rising from $135.55 to $148.99. Shares were essentially flat through Tuesday, closing at $135.97 on Monday and slipping to $135.17 on Tuesday. The decisive catalyst arrived Wednesday, when Merck and Moderna reported a positive Phase III readout for their personalized melanoma therapy, intismeran, showing improved recurrence-free and distant metastasis-free survival; volume surged to 32.8 million shares and the stock closed at $152.20. Merck gave back $3.21 on Thursday, a partial reversal, as investors appeared to consolidate the sharp gain. Lower bond yields and generally supportive equity-market conditions helped the backdrop, but the cancer-therapy news was the material company-specific driver.
MRK rose $3.15, or 2.47%, from $127.77 to $130.92 over the week, with nearly all of the gain arriving on Monday, when the stock advanced $2.34. The clearest company-related support was coverage highlighting Merck’s raised guidance and new KEYTRUDA developments, alongside reports that pipeline progress could lift fair value. The stock then added modestly through Friday, gaining $0.21 on Tuesday, $0.33 on Wednesday, $0.04 on Thursday and $0.21 on Friday, without a material reversal. Trading volume declined from 11.2 million shares on August 3 to 6.0 million on August 10, suggesting the late-week advance occurred on lighter activity. No separate, named analyst rating action was supplied.
-2.90%, from $131.82 to $128.00. Merck declined through July 30, briefly recovered to $130.20 on July 31, then fell 1.87% to $127.77 on August 3 before edging up to $128.00 on August 4. The only identified company-specific catalyst was second-quarter reporting: Merck beat earnings and revenue estimates, raised and narrowed its 2026 sales outlook, and cited strong oncology and newer-product performance. Those positives were tempered by a $1.3 billion GAAP quarterly loss, versus $4.4 billion of profit a year earlier, and a $0.54 loss per share. Because the largest decline preceded the August 4 release, the supplied evidence does not establish that the earnings details caused the weekly drop.
